Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

Diabetologia

Volumn 49, Issue 11, 2006, Pages 2564-2571

  Raz, I ^a   Hanefeld, M ^a   Xu, L ^a   Caria, C ^a   Williams Herman, D ^a   Khatami, H ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN; GLYCOPROTEIN; PLACEBO; PYRAZINE DERIVATIVE; SITAGLIPTIN; TRIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; HUMAN; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ADENOSINE DEAMINASE; ADOLESCENT; ADULT; AGED; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; PLACEBOS; PYRAZINES; TRIAZOLES;

EID: 33845489598     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0416-z     Document Type: Article

References (0)